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The active pharmaceutical ingredient phloroglucinol (PHL) has been taken as
an illustrative molecule to explore the intermolecular interactions which can be
established with other molecular entities to build PHL pharmaceutical co-
crystals. The crystal structures of five newly synthesized co-crystals are reported,
where PHL is crystallized with N-heterocycles, namely 2-hydroxy-6-methylpyr-
idine (1), 2,4-dimethyl-6-hydroxypyrimidine (2), 4-phenylpyridine (3), 2-
hydroxypyridine (4) and 2,3,5,6-tetramethylpyrazine (5). The structural
characteristics of these co-crystals, as far as the hydrogen-bonding networks
and the crystalline architectures are concerned, are strongly dependent on the
chemical features of the coformer molecules, as well as on their size and shape.
A detailed analysis of the intermolecular interactions established in all the PHL
co-crystals of known structures has allowed the recognition of some regularities
in the packing modes that can be useful in the design of new supramolecular
adducts forming predictable structural motifs.
1. Introduction
In the last few years, the design and synthesis of co-crystals
containing active pharmaceutical ingredients (APIs) has
become the new frontier of crystal engineering (Steed, 2013;
Brittain, 2012a,b, 2013; Blagden et al., 2008; Shan & Zawor-
otko, 2008; Sekhon, 2009) due to the great opportunity to
modify the physico-chemical properties of solid forms of
drugs. Actually, in pharmaceutical co-crystals two or more
components (out of which at least one is an API) are assem-
bled through intermolecular interactions which are different
from those found in the crystals of the pure components;
consequently, these new crystalline forms exhibit specific
physical properties, such as dissolution rate, bioavailability,
physical stability etc. depending on the chemical nature of the
co-crystal former, retaining at the same time the unaltered
chemical structure of the APIs (Jones et al., 2006). Currently,
several APIs are known to improve their solubility profile and
bioavailability when co-crystallized with appropriate cofor-
mers (Brittain, 2012a; Childs et al., 2013); this approach seems
to be promising for the development of new pharmaceutical
preparation, even if, as we have recently shown (Ferretti et al.,
2015), co-crystals may induce completely unpredictable effects
on biological systems. The ultimate goal of the pharmaceutical
co-crystal design is the enhancement of the drug performance
without either altering its pharmacological behaviour or
showing undesired effects, producing at the same time new
solid forms having features useful for patent eligibility (Trask,
2007).
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Up to now the most effective co-crystal research (besides
the in-depth understanding of structure-property relation-
ships) relies on an efficient preparation of the desired co-
crystals, which in turn requires an understanding and exploi-
tation of the intermolecular interactions which may occur
between the API and other co-crystal formers to give robust
supramolecular synthons. Since hydrogen bonding is
undoubtedly the most important among the intermolecular
interactions, because it is highly directional and its energy can
be modulated by the chemical environment, the design of a
pharmaceutical co-crystal is based on the identification of
specific hydrogen-bond donor and acceptor groups in APIs in
order to choose a ‘complementary interacting’ molecule that
can act as an efficient co-former.
From a supramolecular perspective, phloroglucinol (1,3,5-
trihydroxybenzene, PHL) is a particularly attractive drug since
it is rigid, i.e. it does not present torsional flexibility, and has
three OH groups that can act as hydrogen-bonding donors and
acceptors; from a chemical point of view it can be classified as
a weak acid (pKa value: 8.45). PHL is normally used as an
antispasmodic agent; it is commercialized in tablets and has
the appearance of a white solid soluble in water (solubility:
10.6 g L1), in alcohols and ethers. In addition, phloroglucinol
and its derivatives exhibit a wide range of effects, such as anti-
inflammatory, cytotoxicity (Barwell et al., 1989), anti-
thrombotic and profibrinolytic activities (Bae, 2011). Precli-
nical studies have proposed the role of phloroglucinol against
the aging process and oxidative stress increasing cell viability
and inhibiting lipid peroxidation (Kang, Lee, Chae et al., 2006;
Kang, Zhang et al., 2010; So & Cho, 2014). Finally, PHL and its
derivatives are included in compositions used as anticancer
(Kim et al., 2015), antidepressant, antimicrobial agents and so
on (Singh et al., 2009).
A survey of the literature has shown that many phloro-
glucinol co-crystals have been obtained, the majority having
an aromatic base as the co-former; in all the structures the
PHL-OH groups interact preferably as hydrogen-bond donors
towards a basic nitrogen, forming the hydroxyl  pyridine
supramolecular heterosynthon which recently has been shown
to have a very high frequency of occurrence in crystals
containing hydroxyl and pyridine moieties (Bis et al., 2007). As
part of our continuing interest in understanding the structural
features of the co-crystallization process (Bertolasi, Gilli et al.,
2001; Bertolasi, Pretto et al., 2002), we decided to synthesize
phloroglucinol co-crystals containing N-heterocycles as co-
formers, i.e. pyridine/pyrimidine/pyrazine derivatives. The
choice of these molecules is also justified from the fact that the
N-heterocyclic skeleton is the basis of many essential phar-
maceuticals and of many physiologically active natural
products. As an example, many pyrimidine and pyrazine
derivatives are found in pharmaceuticals acting against a large
variety of diseases (Selvam et al., 2012; Singh & Chouhan,
2014; Kao et al., 2013; Wu et al., 2013).
The solid-state methodology chosen to prepare the co-
crystals was the slow solvent evaporation of PHL/co-former
solutions, with the aim of obtaining suitable samples for single-
crystal X-ray diffraction experiments. In this article five new
molecular co-crystals are reported, where PHL is co-crystal-
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Table 1
Experimental details.
Experiments were carried out at 295 K with Mo K radiation using a Nonius Kappa CCD. H atoms were treated by a mixture of independent and constrained
refinement.
(1) (2) (3) (4) (5)
Crystal data
Chemical formula C6H6O33C6H7NOH2O C6H6O33C6H8N2O C6H6O32C11H9N C6H6O32C5H5NO 2C6H6O33C8H12N2
Mr 471.50 498.54 436.49 316.31 660.80
Crystal system, space
group
Monoclinic, P21/c Triclinic, P1 Monoclinic, P21/c Monoclinic, P21/c Monoclinic, P21/c
a, b, c (Å) 12.2625 (5), 14.1634 (7),
15.4250 (9)
7.7212 (2), 12.4488 (2),
14.2673 (3)
18.4503 (4), 7.3939 (2),
18.7699 (5)
7.7275 (3), 19.828 (1),
11.3080 (6)
15.6225 (4), 13.5010 (3),
17.2314 (5)
, ,  () 90, 113.8431 (16), 90 112.608 (1), 95.561 (1),
93.541 (1)
90, 114.924 (1), 90 90, 117.679 (2), 90 90, 90.235 (1), 90
V (Å3) 2450.4 (2) 1252.65 (5) 2322.1 (1) 1534.3 (1) 3634.4 (2)
Z 4 2 4 4 4
 (mm1) 0.01 0.01 0.08 0.10 0.08
Crystal size (mm) 0.28  0.14  0.10 0.35  0.17  0.11 0.35  0.26  0.09 0.28  0.20  0.11 0.24  0.20  0.17
Data collection
No. of measured, inde-
pendent and observed
[I > 2(I)] reflections
8382, 4321, 1632 9568, 5979, 4293 10 162, 5582, 2961 4785, 2693, 1170 14 448, 7827, 3828
Rint 0.126 0.023 0.049 0.079 0.052
(sin /)max (Å
1) 0.595 0.661 0.661 0.595 0.639
Refinement
R[F2 > 2(F2)], wR(F2),
S
0.096, 0.325, 1.03 0.061, 0.222, 1.00 0.058, 0.195, 0.95 0.059, 0.191, 1.05 0.071, 0.226, 1.06
No. of reflections 4321 5979 5582 2693 7827
No. of parameters 316 373 394 232 481
No. of restraints 2 0 0 3 0
	max, 	min (e Å
3) 0.69, 0.29 0.32, 0.37 0.16, 0.20 0.27, 0.29 0.24, 0.25
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lized with 2-hydroxy-6-methylpyridine (giving co-crystal 1),
2,4-dimethyl-6-hydroxypyrimidine (giving co-crystal 2), 4-
phenylpyridine (giving co-crystal 3), 2-hydroxypyridine
(giving co-crystal 4) and 2,3,5,6-tetramethylpyrazine (giving
co-crystal 5). Their structural and packing features have been
analysed and compared with those of all PHL–co-crystals
found in the literature, with the aim of assessing the most
recurrent supramolecular synthons, useful information for the
design of new co-crystals having predictable structural motifs.
2. Experimental
2.1. Synthesis of co-crystals
Phloroglucinol and the other co-crystal formers were
purchased from Sigma-Aldrich1, and used without further
purification. All chemicals were of analytical or chromato-
graphic grade.
An equimolar quantity of PHL and co-crystal formers was
dissolved in the minimum quantity of ethanol and left for slow
evaporation at room temperature. Colourless crystals were
observed after a few days.
2.2. X-ray crystallography
Single-crystal diffraction data for the five co-crystals (1)–(5)
were collected on a Nonius Kappa diffractometer equipped
with a CCD detector with graphite-monochromated Mo K
radiation ( = 0.71069 Å). Intensities were corrected for
Lorentz and polarization effects. The structures were solved
by direct methods with the SIR97 suite of programs (Altomare
et al., 1999) and refinement were performed on F2 by full-
matrix least-squares methods with all non-H atoms anisotropic
with SHELXL2014/7 (Sheldrick, 2015). The data diffraction
collected for compound (1) conveyed the poor quality of the
crystals, and this is reflected by the Rint and refinement R-
factors; the structure was however solved and refined without
problems, then allowing the analysis of the intermolecular
interactions and packing features. In (1) the H atoms were
included on calculated positions, riding on their carrier atoms,
apart from those belonging to the water molecule, located in a
difference Fourier map and refined isotropically with
restrained O—H distances. In (2) and (5) all H atoms except
those of the methyl groups, included on calculated positions,
were found in the difference-Fourier map and refined isotro-
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Figure 1
ORTEPIII view and atom-numbering scheme for (a) (1), (b) (2), (c)
(3), (d) (4) and (e) (5). Displacement ellipsoids are drawn at the
40% probability level. Hydrogen bonds are drawn as dashed lines.
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pically. In (3) all the H atoms were found in the difference
Fourier map and refined isotropically; in (4) the H atoms of
the phloroglucinol molecule were found in the difference
Fourier map and refined isotropically, while the others were
included on calculated positions. All calculations were
performed using SHELXL97 (Sheldrick, 2015) implemented
in the WinGX system of programs (Farrugia, 1999). Experi-
mental details are given in Table 1. Tables S1–S5 of bond
distances and angles for compounds (1)–(5), respectively, are
given in the supporting information.
2.3. CSD search
The crystallographic data of the published phloroglucinol
co-crystals were retrieved from the October 2014 release of
the Cambridge Structural Database (Groom et al., 2016). Only
the structures exhibiting no crystallographic disorder have
been considered.
3. Description of the structures
ORTEPIII views of the five co-crystals are shown in Figs.
1(a)–(e). The hydrogen-bonding geometrical parameters are
given in Table 2.
3.1. Crystal structure of PHL–2-hydroxy-6-methylpyridine
(1)
The structural determination shows the presence of a PHL–
coformer–water (1:3:1) co-crystal, the hydroxypyridine mole-
cule being in its pyridone form. The electronic effect of
substituents bonded at position 6 of the 2-hydroxypyridine
derivatives is inductive in character and strongly influences the
position of the tautomeric equilibrium, possibly affecting the
relative acidity of the O—H group with respect to the N—H
group. A consequence of this is that with substituents such as
chloro- or methoxy groups the pyridines are mainly in the
aromatic form, while 2-hydroxy-6-methylpyridine is always in
the pyridone form (Forlani et al., 2002). In the crystal the
pyridone moieties form dimeric units by R22ð8Þ supramolecular
homosynthons (ring A in Fig. 2a) through N—H  O
hydrogen-bonding interactions; each phloroglucinol molecule
links two of these dimers forming bifurcated O—H  O
interactions with the carbonyl O atoms, the last hydroxyl
group being involved in an O—H  O hydrogen bond with
water. The water molecule, in turn, donates two bonds with its
two H atoms acting as both hydrogen-bonding donors and
acceptors to give the R44ð16Þ ring B shown in Fig. 2(a).
3.2. Crystal structure of PHL–2,4-dimethyl-6-hydroxypyri-
midine) (2)
The asymmetric unit of (2) is made of PHL and the
coformer in its ketonic form in a 1:3 ratio. The pyrimidone
moieties are linked in dimers by N—H  O interactions
forming the usual R22ð8Þ ring; at variance with (1), in this case a
second N atom on each pyrimidone ring is free to accept a O—
H  N hydrogen bond from phloroglucinol, in such a way that
three dimers are put together by a unique PHL molecule. The
resulting characteristic pattern is shown in Fig. 2(b).
3.3. Crystal structure of PHL–4-phenylpyridine (3)
In (3) the ratio of PHL–coformer (4-phenylpyridine) is 1:2.
The structural motifs made by O—H  N/O hydrogen bonds
are quite simple: each PHL interacts with two pyridine deri-
vatives via O—H  N bonds of D11ð2Þ type and with two
adjacent phloroglucinol molecules forming O—H  O C11ð6Þ
chains, which run parallel to the c direction and are separated
by layers of 4-phenylpyridine derivatives (Fig. 2c).
3.4. Crystal structure of PHL–2-hydroxypyridine (4)
The asymmetric unit of (4) is composed of PHL and 2-
hydroxypyridine in the ratio 1:2. Even in this case, the pyri-
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Table 2
Hydrogen-bonding parameters (Å, ).
D—H  A D—H D  A H  A D—H  A
Compound (1)
O1—H  O1W 0.82 2.646 (9) 1.87 159
O2—H  O5 0.82 2.663 (7) 1.87 161
O3—H  O4 0.82 2.691 (7) 1.88 172
O1W—H  O6 0.91 (5) 2.738 (8) 1.82 (5) 173 (4)
O1W—H  O2i 0.89 (5) 2.837 (9) 1.98 (8) 162 (7)
N2—H  O5ii 0.86 2.766 (8) 1.91 175
N1—H  O6iii 0.86 2.784 (6) 1.93 171
N3—H  O4iv 0.86 2.799 (6) 1.94 176
(i) x 1;y 1; 1  z; (ii) 1  x;y; 1  z; (iii) x; yþ 1; z; (iv) x; y 1; z.
Compound (2)
O1—H  N1 0.82 (3) 2.900 (3) 2.09 (3) 167 (3)
O2—H  N3 0.80 (3) 2.816 (3) 2.04 (3) 168 (3)
O3—H  N5 0.81 (4) 2.740 (3) 1.96 (4) 160 (3)
N2—H  O4i 1.01 (3) 2.801 (2) 1.78 (3) 179 (3)
N4—H  O6ii 0.89 (3) 2.762 (2) 1.87 (3) 177 (3)
N6—H  O5iii 0.96 (2) 2.824 (2) 1.87 (2) 173 (2)
C2—H  N1 0.94 (3) 3.289 (3) 2.56 (3) 134 (3)
C24—H  O3iv 0.96 3.357 (4) 2.54 143
C4—H  O5v 0.95 (4) 3.573 (3) 2.64 (4) 166 (3)
(i) x; 2  y; 1  z; (ii) x 1; yþ 1; zþ 1; (iii) xþ 1; y 1; z 1; (iv)
1  x;y;z; (v) x; 1  y; 1  z.
Compound (3)
O1—H  N1 0.90 (4) 2.666 (3) 1.76 (4) 175 (4)
O3—H  N2 0.91 (4) 2.748 (3) 1.83 (4) 174 (3)
O2—H  O1i 0.91 (4) 2.717 (2) 1.91 (4) 146 (3)
(i) x; y 1; z
Compound (4)
O1—H  O4 0.82 (4) 2.807 (5) 1.99 (4) 176 (4)
O2—H  O5 0.89 (4) 2.646 (4) 1.77 (4) 165 (4)
O3—H  O2i 0.84 (6) 2.844 (6) 2.02 (6) 167 (5)
N1—H  O5ii 0.90 2.762 (6) 1.86 176
N2—H  O4ii 0.90 2.864 (6) 1.96 177
(i) x; 12  y; zþ 12; (ii) x;y;z 1.
Compound (5)
O1—H  N1 0.98 (5) 2.839 (3) 1.86 (5) 171 (4)
O2—H  N3 0.81 (4) 2.875 (4) 2.08 (4) 167 (4)
O3—H  N5 0.87 (5) 2.833 (3) 2.01 (5) 158 (4)
O4—H  N6 0.91 (4) 2.840 (4) 2.00 (4) 152 (3)
O5—H  N4i 0.85 (4) 2.848 (4) 2.00 (4) 174 (4)
O6—H  N2i 1.04 (6) 2.823 (4) 1.77 (6) 169 (5)
C6—H3  O2ii 1.02 (3) 3.283 (4) 2.27 (3) 171 (3)
C32—H5  O6iii 0.94 (3) 3.273 (4) 2.33 (3) 173 (3)
(i) xþ 1; y; zþ 1; (ii) 1  x; y 12 ; 12  z; (iii) 2  x; yþ 12 ; 32  z.
electronic reprint
done tautomer is present and the coformer molecules are
linked in dimers by N—H  O interactions forming R22ð8Þ
rings. Two dimers are connected to one PHL molecule [D11ð2Þ
motif] which in turn uses its third OH group to form O—
H  O hydrogen bonds with adjacent drug molecules [C11ð6Þ
motif]. The final packing is made of parallel zigzag ribbons
running along the b direction (Fig. 2d).
3.5. Crystal structure of PHL–2,3,5,6-tetramethylpyrazine (5)
The stoichiometry for co-crystal (5) is PHL–pyrazine (2:3).
The three pyrazine moieties are crystallographically different
since one of them simply bridges two drug molecules through
its N atoms located at the opposite site of the molecule, while
the others are both linked to the same phloroglucinol mole-
cules, as shown in Fig. 1(e). These four molecules form a
R44ð22Þ ring (Fig. 2e)
4. Hydrogen-bonding analysis
As discussed in the previous paragraph, the three OH groups
of the phloroglucinol molecule are all involved in hydrogen
bonds acting always as donors (only sometimes as acceptors).
With the aim of gaining deeper insight into the PHL
hydrogen-bonding capability, a search of the CSD (Groom et
al., 2016) has been performed of all its co-crystals of known
structure. Excluding disordered structures, 30 entries have
been found (Santra & Biradha, 2011; Boldog et al., 2004;
Haberhauer et al., 2004; Ung et al., 1994; Biradha & Zawor-
otko, 1998; Gao et al., 2008; Arora et al., 2009; Bis et al., 2007;
Santra & Biradha, 2008; Sarma et al., 2008; Mahapatra et al.,
2010; Lavender et al., 1998; Shi et al., 2010; Ghosh et al., 2005;
Coupar et al., 1996; Barooah et al., 2003; Vishweshwar et al.,
2003; Imai et al., 2009; Hou et al., 2010; Liu et al., 2001), two of
which are simple solvated PHL [solvent: dimethylsulfoxide
(Polyanskaya et al., 2011) and water (Thomas et al., 2011)]. The
complete list of CSD entries, together with information on the
co-crystals’ composition and donor  acceptor distances of
O—H(hydroxyl)  X interactions, considering only those in
which the PHL hydroxyl group acts as a donor, are reported in
Table S6 of the supporting information. There are three types
of acceptor atoms: nitrogen (in most cases aromatic N),
oxygen (carbonylic or hydroxylic) and OW from water
molecules. The donor  acceptor distance distributions are
shown in the two histograms of Fig. 3(a) and (b) for O  N and
O  O, respectively. The O  N distances vary in the quite
research papers
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Figure 2
Packing arrangements for co-crystals (a) (1), (b) (2), (c) (3), (d) (4)
and (e) (5).
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large range 2.59–2.95 Å, while the O  O narrower range is
2.60–2.89 Å. In a recent paper (Alvarez, 2013) the distribution
of distances in the CSD between two specific atoms has been
extensively analyzed and the relative histograms for diverse
atomic couples extracted, distinguishing between simple van
der Waals contacts and hydrogen bonds. According to these
distributions, the structural parameters found in PHL co-
crystals show that the O—H  N interactions listed in Table S1
can be classified as strong/medium hydrogen bonds.
On the basis of the pKa equalization principle (Gilli et al.,
2009), the strongest hydrogen bonds are associated with a very
low pKa value, i.e. the difference between donor and
acceptor acidic constants. The pKa value associated with a
general D—H  A interaction is calculated as
pKaðDH   AÞ ¼ pKAHðDHÞ  pKþBHðAHþÞ:
The wide O  N distance distribution described above can
then be correlated to the chemical diversity, expressed in
terms of acidity constant, displayed by the coformer molecules
in PHL co-crystals. As shown in Table 3, the coformer pKa
values range from 0.6 to 6.95. The plot of pKa versus N  O
is shown in Fig. 4. Despite the many approximations used
(mean value of N  O distances; pKa value sometimes not
exactly corresponding to the coformer molecule but to similar
molecular entities), a linear trend is clearly visible, indicating
that this system is a good example of the validity of the pKa
equalization principle.
5. Role of water molecules in co-crystal structures
Out of 34 PHL co-crystal structures, 16 have co-crystallized
solvent molecules. In 11 cases the solvent turns out to be
water. As stated by Clarke et al. (2010), ‘water is indeed in
many ways the nemesis of crystal engineering’ and, accordingly,
even in this case the presence of co-crystallized water mole-
cules makes it difficult to rationalize the hydrogen-bonding
network. A general finding for PHL co-crystals is that the
water molecules are present when the coformers have an
overabundance of hydrogen-bonding donor or acceptor
groups, and a possible explanation could be the requirement
of maximizing the interactions among the entities constituting
the crystal. On the other hand, there is no rule about the
number of water molecules in the asymmetric unit (from one
to four, see Table S6) or the stoichiometric ratio among the co-
crystal’s components. Moreover, the water molecules could in
principle compete with the PHL-OH groups for the formation
of hydrogen bonds with the coformer molecules. To explore
this possibility, hydrogen-bond propensities (Galek et al.,
2007) were calculated using the program Mercury 3.5.1.
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Table 3
O  N distances (Å) and coformer pKa in phloroglucinol co-crystals with
mean values in angle brackets.
CSD code
O  N
distance
hmeani Coformer pKa pKa Reference
(3)a h2.707i 4-Phenylpyridine: 5.5 2.95 Bansal (1999)
(5)a h2.843i Tetramethyl pyrazine:
2.88
5.62 Keyworth (1959)
HAHNOUb 2.741 2,20-Bipyridine: 4.34 4.11 Martell et al. (2001)
HIMGALc 2.741 4-Methylpyridine:
6.02
2.43 Braude & Nachod
(1955)
HIMGEPc h2.738i 2,4-Dimethylpyridine:
6.72
1.73 Clarke & Rothwell
(1960)
HODLESd h2.615i Imidazole: 6.95 1.50 Bruice & Schmir
(1958)
KIHZEHe h2.766i 4-Cyanopyridine: 1.90 6.55 Gramstad (1993)
MORVEVf h2.831i Phenazine: 1.23 7.22 Albert & Phillips
(1956)
MORVIZf h2.852i Phenazine: 1.23 7.22 Albert & Phillips
(1956)
MORVOFf h2.663i Acridine: 5.60 2.85 Braude & Nachod
(1955)
MORVULf h2.805i Phenazine: 1.23 7.22 Albert & Phillips
(1956)
PUPGOXg 2.846 Caffeine: 0.61 7.84 Hodgman (1951)
PUVMICh h2.798i 2,20-Bipyridine: 4.34 4.11 Martell et al. (2001)
RAWDIC01i h2.717i Urotropine: 4.89 3.56 Cooney et al. (1986)
TEKKOIj h2.741i 4,40-Bipyridine: 4.96 3.49 Ashton et al. (1982)
VAKVEJk h2.775i Nicotinamide: 3.33 5.12 Gressel & Gallelli
(1968)
References: (a) present work; (b) Haberhauer et al. (2004); (c) Biradha & Zaworotko
(1998); (d) Gao et al. (2008); (e) Bis et al. (2007); (f) Sarma et al. (2008); (g) Mahapatra et
al. (2010); (h) Lavender et al. (1998); (i) Ghosh et al. (2005); (j) Coupar et al. (1996); (k)
Vishweshwar et al. (2003).
Figure 3
Histograms of donor  acceptor distances (Å) in O—H  X (X = N, O)
hydrogen-bonding interactions found in phloroglucinol co-crystals.
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Hydrogen-bond propensity is based on a statistical model
making use of the molecular information stored in the
Cambridge Structural Database (CSD). The dataset for this
model is made of molecules containing one or more of the
functional groups present in a given target system. The exis-
tence of a hydrogen bond between potential donor and
acceptor atoms is decided using distance and angle criteria. A
hydrogen-bond propensity for a donor–acceptor pair is a value
between 0 and 1, where 0 indicates no likelihood of a
hydrogen-bond formation and 1 indicates that a hydrogen
bond is always formed. In view of the PHL–co-crystal types
found, the entry VAXVEI [phloroglucinol bis(isonicotin-
amide) dihydrate] has been chosen as a target system. It is
characterized by three functional groups: water, phenyl-OH
(O of ar-hydroxy), aromatic N. The obtained values of the
propensity for the considered functional groups are listed in
Table 4. It is interesting to note that the highest propensity
value is associated with hydrogen bonds formed between
water molecules and aromatic N; however, a close examina-
tion of the PHL–co-crystals reveals that in these systems the
water molecules interact rarely with the aromatic N atoms,
most frequently acting as H-donors towards other water
molecules, OH or C O groups [see for example the inter-
action lists for compound (1)]. In addition, no conserved
supramolecular motif could be found in hydrated structures,
therefore no classification is possible. In almost all the struc-
tures, the co-crystallized water molecules exploit the full range
of their hydrogen-bonding capability, acting both as hydrogen-
bond donors and acceptors. In view of this, it can be assumed
that their presence could provide a considerable contribution
to the crystal stability; for example, Fucke et al. (2013) have
recently shown that the hydrogen-bonding network involving
the solvent molecules in hydrated Piroxicam is one of the
major stabilizing factors of the crystal structure with respect to
the non-hydrated drug.
6. Packing comparison: non-solvated structures
Considering the number of functional groups present in the
co-former molecules and other chemical characteristics such
as size and shape, it is possible to distinguish different ways of
packing. When the coformer molecule has only one hydrogen-
bond acceptor functional group [(3), HIMGAL, HIMGEP
(Biradha & Zaworotko, 1998), KIHZEH (Bis et al., 2007),
MORVOF (Sarma et al., 2008)] the packing is determined by
the relative sizes of PHL and the coformer. KIHZEH (Bis et
al., 2007) has been included in this group in view of the fact
that the phenyl-cyano group is a poor hydrogen-bond
acceptor. If the two molecules have strictly comparable
molecular size, the stoichiometric PHL:coformer ratio is 1:3
and an isolated supramolecular complex is formed. An
example is reported in Fig. 5(a).
Conversely, when the size of the co-former is much larger,
the steric hindrance prevents the formation of the supramo-
lecular aggregation of Fig. 5(a) and the PHL:coformer ratio
changes to 1:2. In the two structures [(3), MORVOF Sarma et
al., 2008], representative of such a situation, the packing motif
is the same. It is characterized by parallel C11ð6Þ chains formed
by the O—H  O bonded phloroglucinol molecule, in which
two out of three OH groups are involved. The third ‘free’
hydroxyl, as well as that acting as a hydrogen-bond acceptor in
the main chain, are linked through O—H  N interactions
with the co-former molecules, which are organized on both
sides of the chain in a perpendicular way (Figs. 2c and 5b).
Interestingly, the same crystal packing mode is found for (4)
(Fig. 2d). Actually, this co-crystal can rationally be included in
this last group, since the dimeric pyridine unit behaves as a
unique molecule as far as the crystal packing is concerned. As
a matter of fact, the cyclic amide hydrogen-bonded homo-
dimer is a robust synthon which is highly conserved. In the
CSD 445 entries containing such a molecular group have been
found (organic structures only), with a mean N  O distance
of 2.79 (5) Å. In six co-crystal structures, i.e. (5), HOPKAZ
(Arora et al., 2009), MORVEV, MORVUL (Sarma et al.,
2008), PUVMIC (Lavender et al., 1998), RAWDIC01 (Ghosh
et al., 2005) and TEKKOJ (Coupar et al., 1996), the co-crys-
tallized molecule has two (in one case, RAWDIC01, three)
hydrogen-bonding acceptor groups, located on opposite sides.
The 1:3 PHL–coformer stoichiometric ratio in this case is
never observed, being 1:2 or 2:3. In all cases a peculiar packing
mode is recognizable, since each PHL molecule binds two co-
former molecules on one side and one on the other side,
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Table 4
Predicted intermolecular hydrogen-bond propensities (applied to
VAKVEI).
Donor Acceptor Propensity
Lower
bound
Upper
bound
O of water N of aromatic_nitrogen 0.83 0.81 0.84
O of water O of water 0.66 0.65 0.66
O of ar_hydroxy N of aromatic_nitrogen 0.61 0.58 0.64
O of water O of ar_hydroxy 0.41 0.38 0.43
O of ar_hydroxy O of water 0.38 0.36 0.40
O of ar_hydroxy O of ar_hydroxy 0.18 0.17 0.20
Figure 4
pKa versus O  N distances (Å) in PHL co-crystals.
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forming a zigzag ribbon motif (with alternating PHL–
coformer molecule layers). In this case the size and shape of
the co-crystallized molecule is irrelevant: it can be of the same
size and shape as the phloroglucinol (5, Fig. 2e), it can be
planar with a different size (e.g. TEKKOJ, Fig. 5c) or it can be
different in size and shape (RAWDIC01, Fig. 5d).
Analogous to the previous case, compound (2) can be
included in this group of co-crystals, considering the dimeric
unit as a unique block. The packing motif just described is
nicely reproduced (Fig. 2b).
Finally, when the co-former molecule has both hydrogen-
bonding donor and acceptor groups [HIBHEF (Ung et al.,
1994), ULAZEM (Barooah et al.,
2003), XIBQUU (Liu et al., 2001)],
each OH group belonging to the
drug molecule acts as both a
hydrogen-bonding donor and
acceptor. It is interesting to note
that when the size of the coformer
molecule is small enough
(HIBHEF, XIBCUU), the PHL
moiety is surrounded by six mole-
cules in a way resembling what is
found in the pure phloroglucinol
crystal (Görbitz et al., 2008; see Fig.
6)
7. Conclusions
A detailed analysis of the
hydrogen-bonding intermolecular
interactions and packing modes in
pharmaceutical co-crystals
containing the API ploroglucinol
has been presented. As expected,
the phenolic OH groups of the
phloroglucinol molecule, which
have an acidic character, readily
interact with basic groups, in parti-
cular aromatic nitrogens. More-
over, these groups, which in
principle can act both as a
hydrogen-bonding donor or
acceptor, preferentially form O—
H  N interactions whose strength
can be reasonably predicted on the
base of the pKa equalization prin-
ciple. The packing modes of the
PHL–co-crystals can be rationa-
lized on the basis of the chemical
characteristics of the co-former
molecules, such as their size, shape
and number of functional groups.
Furthermore, it has been shown
that robust supramolecular
synthons, such as amide  amide
hydrogen-bonded dimers, can be
considered just like unique mole-
cules as far as the description of the
crystalline architecture is
concerned. Finally, the packing
rationalization was possible for the
hydrated structures, although the
research papers
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Figure 6
Hydrogen-bonding arrangement around the PHL molecule in HIBHEF (coformer: 2,8-dimethyl tricyclo-
syn-2,syn-8-diol; Ung et al., 1994) and in pure phloroglucinol PHGLOL01 (Görbitz et al., 2008).
Figure 5
Hydrogen-bonding motifs in CSD entries: (a) HIMGAL (coformer: 4-methylpyridine; Biradha &
Zaworotko, 1998); (b) MORVOF (coformer: acridine; Sarma et al., 2008); (c) TEKKOJ (coformer: 4,40-
bipyridine; Coupar et al., 1996); (d) RAWDIC01 (coformer: urotropine; Ghosh et al., 2005).
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high number of interactions in which the co-crystallized water
molecules participate suggest they could contribute to the
overall stability of the crystal.
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